Medscape

FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds

Today, the US Food and Drug Administration (FDA) approved prademagene zamikeracel cellular sheets (pz-cel, Zevaskyn), the first autologous cell-based gene therapy for treating wounds in adults and ...
Medical Xpress

Q&A: Two decades of research lead to treatment for rare, painful skin condition

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to blistering and, eventually, large, open wounds that never heal, causing immense pain ...
Medscape

First Patient With Recessive Dystrophic Epidermolysis Bullosa Treated With New Gene Therapy

This week marked the first time a patient with recessive dystrophic epidermolysis bullosa (RDEB) received prademagene zamikeracel (pz-cel, Zevaskyn), a first-of-its-kind autologous gene therapy to ...
Nasdaq

Abeona Therapeutics Announces Publication of Positive Phase 3 VIITAL Study Results for ZEVASKYN™ in Treatment of Wounds from Recessive Dystrophic Epidermolysis Bullosa (RDEB)

ZEVASKYN™ shows significant wound healing and pain reduction in RDEB patients, marking a breakthrough treatment option approved by the FDA. ZEVASKYN is the first and only autologous cell-based gene ...
Nasdaq

Abeona Therapeutics Receives FDA Approval for ZEVASKYN™ as First Gene Therapy for Wounds in Recessive Dystrophic Epidermolysis Bullosa Patients

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...
The Nassau Guardian

Dispelling wound care myths

Most people have had a cut, scrape, or even a burn that required some wound care. Maybe you rinsed it off, let it dry out, or ...